Mirikizumab | Interleukin Related interleukin-related.com

Product Name :
Mirikizumab

Search keywords :
Mirikizumab

drugId :
null

Target Vo:
Interleukin-23 subunit p19

Target Vo Short Name :
IL-23p19

Moa_Name:
Interleukin-23 subunit p19 inhibitors

First Approval Country :
Japan

First Approval Date Filter:
2023

Origin Company_Name :
Eli Lilly And Company

Active Company_Name :
Eli Lilly And Company

Active Indication_Name:
Colitis, Ulcerative

In Active Indication_Name:

Termination Status :

China Termination Status :

Highest Status:
Approved

China Highest Status:
Phase 3 Clinical

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
FEN1 Antibody (YA765)
CD68 Antibody (YA529)
FGFR1 Antibody: FGFR1 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 100,140 kDa, targeting to FGFR1. It can be used for WB,ICC/IF assays with tag free, in the background of Human.

Author: Interleukin Related

Related Posts